Viral filtration testing is a critical part of the product development process for biotherapeutics like vaccines, gene therapies, and biologics. During this testing, samples of the product are subjected to various methods to remove or inactivate potential viral contaminants. The goal is to ensure any viruses that may have been present in the initial raw materials or production methods are eliminated by the downstream purification process. This helps guarantee the final product is safe for patient use.
Viral filtration studies are generally performed on development samples to validate the robustness of the manufacturing process for removing or inactivating viruses. Tests are conducted on unpurified samples, intermediates, and the final product to establish the ability of purification steps to effectively clear potential viral contaminants. Multiple orthogonal methods are used to mimic real-world virus binding and removal under conditions representative of commercial-scale production.
Validation Of Viral Clearance Across Multiple Production Steps
Comprehensive viral filtration validation involves testing samples at various points in the production process. Early stage samples prior to any purification steps are tested to represent a "worst case" scenario with the highest potential viral load. Intermediate samples after some but not all purification steps provide data on intermediate viral clearance capabilities.
Final product samples subjected to the full downstream purification are also tested to confirm sufficient overall viral filtration is achieved. Multiple independent production runs are typically tested to verify consistent performance. This approach accounts for any variability that may occur across manufacturing runs or equipment used.
The same panel of model viruses are used to spike and challenge all sample types. Common viral types representative of potential process contaminants, like pseudorabies virus (PRV), are utilized. Testing multiple sample points allows calculation of the log reduction value (LRV), which confirms the magnitude of viral filtration achieved by sequential purification steps. LRVs can then be totaled to confirm acceptable overall safety margins are achieved.
Analytical Methods For Sensitive Viral Detection
Leading viral filtration studies require the use of highly sensitive detection methods. No single technology can reliably detect all potential viral contaminants, so compliant studies employ a combination of orthogonal analytical approaches. Cell culture assays remain the gold standard due to their ability to detect even non-replicating virions. However, molecular techniques have emerged as important complementary methods.
Cell-based assays involve challenging a monolayer of susceptible cells with the spiked product sample and monitoring for any resulting cytopathic effect. While powerful, they are dependent on the virus being able to replicate in that cell line. Molecular assays based on polymerase chain reaction (PCR) target distinct viral nucleic acids. PCR allows for precise quantification and is not reliant on infectivity, enabling detection of some inactivated particles missed by cell culture.
Latest mass spectrometry techniques are also gaining adoption. Through detection of viral proteins, peptides or non-natural amino acid signatures introduced during viral particle engineering, mass spectrometry provides a uniquely diverse analytical approach. Combining the strengths and non-overlapping detection profiles of cell-based, molecular and protein detection methods delivers high assurance of an exhaustive viral risk assessment.
Advancing Viral Clearance Methodologies
As biomanufacturing processes continue to evolve with new product modalities, analytical technologies for viral filtration studies must also progress. Areas of research include developing even more sensitive cell lines capable of propagating a wider variety of virus families. Methods for concentrating viral particles from large sample volumes improve the ability to detect trace contaminants.
Implementation of microfluidic cell culture platforms could enhance cell-based assays for small sample volumes. Significant efforts focus on expanding the virus types and strains detectable by PCR. Advanced molecular techniques like next generation sequencing hold promise for a universal, culture-independent method. Standardization of mass spectrometry protocols would further leverage its unique capabilities.
Machine learning applications also show potential. By training algorithms on large historical viral detection datasets, artificial intelligence may become capable of predicting clearance performance of new processes without requiring empirical validation studies. Overall, advancements in analytical methodologies will be critical to ensure the stringent viral safety requirements of novel therapies continue to be met as biomanufacturing technologies advance into new domains.
The comprehensive Viral Clearance validation studies employing sensitive and complementary methods are essential for assuring the safety of biopharmaceutical products. Robust testing of process intermediates and final samples verifies multiple log reductions of potential viral contaminants are achieved through production. Advanced analytical technologies further enhance the reliability of these critical safety assessments to support patient access to novel life-changing therapies.
Get more insights on this topic: https://www.dailyprbulletin.com/understanding-viral-clearance-in-biologics/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it